Relationship between plasmatic activity of type 1 plasminogen activator inhibitor and the presence of risk factors in patients with type II diabetes

CRESPI NORA; SCICOLONE ALEJANDRO; SANCHEZ VIVIANA; SCICOLONE GABRIEL

Espeña

Congreso; The XVI World Congress of Cardiology 2008; 2008

Levels of type1 plasminogen activator inhibitor (PAI-1) in plasma have been related to bad prognosis in patients bearing pathologies that affect cardiovascular system. Although, the functional role of PAI-1 can be only estimated by its active molecular form, major part of works have studied the antigenic levels of this molecule without differentiating the active and the latent molecular forms. This work aims at investigating whether the plasmatic activity of PAI-1 is increased in patients bearing type II diabetes –a metabolic pathology that affects cardiovascular system and is related, in pathogenic mechanisms, to other cardiovascular diseases- and whether this increase is higher in patients with cardiovascular risk factors such as: essential arterial hypertension or target organ damage. Methods: An ELISA assay was used to measure the active PAI-1 in plasma samples of 60 ambulatory patients received in “Agote” Centre of Health for presenting type II diabetes (28) or for other reasons (32). Plasmatic PAI-1 activity was compared between diabetic and non-diabetic patients, and among different groups of patients constituted by the presence or lack of type II diabetes, stage I or II essential arterial hypertension and target organ damage. Student test was used to compare two groups of patients and one way ANOVA with Tukey postest was used to compare three or more groups of patients. Two ways ANOVA was used to establish the relative level of importance of the different pathologic conditions in the PAI-1 variability. P0.05 was considered statistically significant. Results: The plasmatic PAI-1 activity is higher in patients with type II diabetes (p0.0067). Among diabetic patients, the PAI-1 activity significantly increases when essential arterial hypertension (p0.01) or target organ damage (p0.029) are added. Among diabetic patients with target organ damage, the cardiac lesion presents the most significant increase in PAI-1 activity (p0.0001). Two ways ANOVA shows that the increase in plasmatic PAI-1 activity depends, in a decreasing level of importance, on the presence of type II diabetes, stage II essential arterial hypertension and target organ damage. Conclusions: The plasmatic activity of PAI-1 increases in patients with type II diabetes and this increase is higher when stage II essential arterial hypertension and/or target organ damage (mainly cardiac lesion) are added. This suggests that plasmatic activity of PAI-1 is related to the severity of type II diabetes and it could be useful as a predictive parameter to follow the evolution of these patients. aims at investigating whether the plasmatic activity of PAI-1 is increased in patients bearing type II diabetes –a metabolic pathology that affects cardiovascular system and is related, in pathogenic mechanisms, to other cardiovascular diseases- and whether this increase is higher in patients with cardiovascular risk factors such as: essential arterial hypertension or target organ damage. Methods: An ELISA assay was used to measure the active PAI-1 in plasma samples of 60 ambulatory patients received in “Agote” Centre of Health for presenting type II diabetes (28) or for other reasons (32). Plasmatic PAI-1 activity was compared between diabetic and non-diabetic patients, and among different groups of patients constituted by the presence or lack of type II diabetes, stage I or II essential arterial hypertension and target organ damage. Student test was used to compare two groups of patients and one way ANOVA with Tukey postest was used to compare three or more groups of patients. Two ways ANOVA was used to establish the relative level of importance of the different pathologic conditions in the PAI-1 variability. P0.05 was considered statistically significant. Results: The plasmatic PAI-1 activity is higher in patients with type II diabetes (p0.0067). Among diabetic patients, the PAI-1 activity significantly increases when essential arterial hypertension (p0.01) or target organ damage (p0.029) are added. Among diabetic patients with target organ damage, the cardiac lesion presents the most significant increase in PAI-1 activity (p0.0001). Two ways ANOVA shows that the increase in plasmatic PAI-1 activity depends, in a decreasing level of importance, on the presence of type II diabetes, stage II essential arterial hypertension and target organ damage. Conclusions: The plasmatic activity of PAI-1 increases in patients with type II diabetes and this increase is higher when stage II essential arterial hypertension and/or target organ damage (mainly cardiac lesion) are added. This suggests that plasmatic activity of PAI-1 is related to the severity of type II diabetes and it could be useful as a predictive parameter to follow the evolution of these patients. Methods: An ELISA assay was used to measure the active PAI-1 in plasma samples of 60 ambulatory patients received in “Agote” Centre of Health for presenting type II diabetes (28) or for other reasons (32). Plasmatic PAI-1 activity was compared between diabetic and non-diabetic patients, and among different groups of patients constituted by the presence or lack of type II diabetes, stage I or II essential arterial hypertension and target organ damage. Student test was used to compare two groups of patients and one way ANOVA with Tukey postest was used to compare three or more groups of patients. Two ways ANOVA was used to establish the relative level of importance of the different pathologic conditions in the PAI-1 variability. P0.05 was considered statistically significant. Results: The plasmatic PAI-1 activity is higher in patients with type II diabetes (p0.0067). Among diabetic patients, the PAI-1 activity significantly increases when essential arterial hypertension (p0.01) or target organ damage (p0.029) are added. Among diabetic patients with target organ damage, the cardiac lesion presents the most significant increase in PAI-1 activity (p0.0001). Two ways ANOVA shows that the increase in plasmatic PAI-1 activity depends, in a decreasing level of importance, on the presence of type II diabetes, stage II essential arterial hypertension and target organ damage. Conclusions: The plasmatic activity of PAI-1 increases in patients with type II diabetes and this increase is higher when stage II essential arterial hypertension and/or target organ damage (mainly cardiac lesion) are added. This suggests that plasmatic activity of PAI-1 is related to the severity of type II diabetes and it could be useful as a predictive parameter to follow the evolution of these patients. 0.05 was considered statistically significant. Results: The plasmatic PAI-1 activity is higher in patients with type II diabetes (p0.0067). Among diabetic patients, the PAI-1 activity significantly increases when essential arterial hypertension (p0.01) or target organ damage (p0.029) are added. Among diabetic patients with target organ damage, the cardiac lesion presents the most significant increase in PAI-1 activity (p0.0001). Two ways ANOVA shows that the increase in plasmatic PAI-1 activity depends, in a decreasing level of importance, on the presence of type II diabetes, stage II essential arterial hypertension and target organ damage. Conclusions: The plasmatic activity of PAI-1 increases in patients with type II diabetes and this increase is higher when stage II essential arterial hypertension and/or target organ damage (mainly cardiac lesion) are added. This suggests that plasmatic activity of PAI-1 is related to the severity of type II diabetes and it could be useful as a predictive parameter to follow the evolution of these patients. Results: The plasmatic PAI-1 activity is higher in patients with type II diabetes (p0.0067). Among diabetic patients, the PAI-1 activity significantly increases when essential arterial hypertension (p0.01) or target organ damage (p0.029) are added. Among diabetic patients with target organ damage, the cardiac lesion presents the most significant increase in PAI-1 activity (p0.0001). Two ways ANOVA shows that the increase in plasmatic PAI-1 activity depends, in a decreasing level of importance, on the presence of type II diabetes, stage II essential arterial hypertension and target organ damage. Conclusions: The plasmatic activity of PAI-1 increases in patients with type II diabetes and this increase is higher when stage II essential arterial hypertension and/or target organ damage (mainly cardiac lesion) are added. This suggests that plasmatic activity of PAI-1 is related to the severity of type II diabetes and it could be useful as a predictive parameter to follow the evolution of these patients. 0.0067). Among diabetic patients, the PAI-1 activity significantly increases when essential arterial hypertension (p0.01) or target organ damage (p0.029) are added. Among diabetic patients with target organ damage, the cardiac lesion presents the most significant increase in PAI-1 activity (p0.0001). Two ways ANOVA shows that the increase in plasmatic PAI-1 activity depends, in a decreasing level of importance, on the presence of type II diabetes, stage II essential arterial hypertension and target organ damage. Conclusions: The plasmatic activity of PAI-1 increases in patients with type II diabetes and this increase is higher when stage II essential arterial hypertension and/or target organ damage (mainly cardiac lesion) are added. This suggests that plasmatic activity of PAI-1 is related to the severity of type II diabetes and it could be useful as a predictive parameter to follow the evolution of these patients. 0.01) or target organ damage (p0.029) are added. Among diabetic patients with target organ damage, the cardiac lesion presents the most significant increase in PAI-1 activity (p0.0001). Two ways ANOVA shows that the increase in plasmatic PAI-1 activity depends, in a decreasing level of importance, on the presence of type II diabetes, stage II essential arterial hypertension and target organ damage. Conclusions: The plasmatic activity of PAI-1 increases in patients with type II diabetes and this increase is higher when stage II essential arterial hypertension and/or target organ damage (mainly cardiac lesion) are added. This suggests that plasmatic activity of PAI-1 is related to the severity of type II diabetes and it could be useful as a predictive parameter to follow the evolution of these patients. 0.0001). Two ways ANOVA shows that the increase in plasmatic PAI-1 activity depends, in a decreasing level of importance, on the presence of type II diabetes, stage II essential arterial hypertension and target organ damage. Conclusions: The plasmatic activity of PAI-1 increases in patients with type II diabetes and this increase is higher when stage II essential arterial hypertension and/or target organ damage (mainly cardiac lesion) are added. This suggests that plasmatic activity of PAI-1 is related to the severity of type II diabetes and it could be useful as a predictive parameter to follow the evolution of these patients. Conclusions: The plasmatic activity of PAI-1 increases in patients with type II diabetes and this increase is higher when stage II essential arterial hypertension and/or target organ damage (mainly cardiac lesion) are added. This suggests that plasmatic activity of PAI-1 is related to the severity of type II diabetes and it could be useful as a predictive parameter to follow the evolution of these patients.